Dctd tumor tissue acquisition
Ended Awarded Last action
- Contract number
- HHSN26100036
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,624,297
Award facts
- Opportunity
-
- N01CO5240180 Solicitation number
- Operations and Technical Support for the Frederick National Laboratory for Cancer Research (FLNCR), a Federally Funded Research and Development Center (FFRDC) Award Notice · Posted Apr 27, 2015
- Contract value 100% obligated
- $2,624,297.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 561210 Facilities Support Services
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Cost No Fee
- Place of performance
- Frederick, MD 21702, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $41,892 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $2,582,405 |
About this award
This is a federal contract award to Leidos Biomedical Research Inc. by the National Cancer Institute (NCI), a civilian agency, for the Delivery Order "DCTD TUMOR TISSUE ACQUISITION". The contract has a ceiling value of $2,624,297.00 and was awarded on September 19, 2016, with an ultimate completion date of September 18, 2021. The contract is a Delivery Order and uses a Cost No Fee pricing type. There is no set-aside designation for this award. Leidos Biomedical Research Inc. is a subsidiary of Leidos Holdings, Inc. that serves as a Federally Funded Research and Development Center (FFRDC) contractor for the NCI, providing a range of biomedical research and facilities support services to federal agencies, with a focus on the National Institutes of Health (NIH). The contract is potentially part of a larger Indefinite Delivery Contract from the NCI valued at up to $6.6 billion over 5 years, under which Leidos Biomedical Research Inc. delivers services through individual task orders.
Quick answers
Who was awarded contract HHSN26100036?
HHSN26100036 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 19, 2016.
How much is contract HHSN26100036 worth?
The government has obligated $2,624,297 on HHSN26100036.
Is contract HHSN26100036 an order under another contract?
Yes. HHSN26100036 is a delivery order under HHSN261201500003I, an indefinite delivery contract.
Was contract HHSN26100036 competed?
The extent of competition for HHSN26100036 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award